These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38700892)

  • 1. Lamivudine plus dolutegravir as a switch strategy in children: three case reports.
    Labate L; Bartalucci C; Taramasso L; Brucci G; Vena A; Bassetti M; Di Biagio A
    New Microbiol; 2024 May; 47(1):111-115. PubMed ID: 38700892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
    Suárez-García I; Alejos B; Ruiz-Algueró M; García Yubero C; Moreno C; Bernal E; Pérez-Is L; Zubero Z; de Zárraga Fernández MA; Samperiz Abad G; Jarrín I;
    J Int AIDS Soc; 2021 Jul; 24(7):e25758. PubMed ID: 34291580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
    BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
    HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
    Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis.
    Hou H; Ba H; Jin X; Luo P; Zhang Y; Li J; Jin J
    Medicine (Baltimore); 2024 Jul; 103(27):e38558. PubMed ID: 38968505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.
    Turkova A; Chan MK; Kityo C; Kekitiinwa AR; Musoke P; Violari A; Variava E; Archary M; Cressey TR; Chalermpantmetagul S; Sawasdichai K; Ounchanum P; Kanjanavanit S; Srirojana S; Srirompotong U; Welch S; Bamford A; Epalza C; Fortuny C; Colbers A; Nastouli E; Walker S; Carr D; Conway M; Spyer MJ; Parkar N; White I; Nardone A; Thomason MJ; Ferrand RA; Giaquinto C; Ford D;
    Contemp Clin Trials; 2024 Jul; 142():107540. PubMed ID: 38636725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
    van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
    Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
    Michienzi SM; Schriever CA; Badowski ME
    Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
    Walmsley S; Smith DE; Górgolas M; Cahn PE; Lutz T; Lacombe K; Kumar PN; Wynne B; Grove R; Bontempo G; Moodley R; Okoli C; Kisare M; Jones B; Clark A; Ait-Khaled M
    AIDS Res Ther; 2024 Mar; 21(1):17. PubMed ID: 38515183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
    Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
    Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir plus lamivudine for the treatment of HIV-1 infection.
    Ciccullo A; Baldin G; Borghetti A; Di Giambenedetto S
    Expert Rev Anti Infect Ther; 2020 Apr; 18(4):279-292. PubMed ID: 32067525
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
    Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
    Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
    Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
    HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
    Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
    Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.